Current studies into retatrutide, a dual agonist for GLP-1 and GIP receptors, are demonstrating significant outcomes in treating weight gain and related non-insulin-dependent diabetes. Initial data suggest a novel https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/